Outperform Cancer

Every time a cancer treatment fails, patients lose something valuable: time.They also endure unnecessary side effects, experience tremendous uncertainty, and may lose the opportunity to receive a treatment that could have worked better.What if choosing a cancer treatment became less trial-and-error and more data-driven?In this episode of Outperform Cancer, Marybeth Gilliam speaks with Edward Chow, Ph.D., Chief Scientific Officer and Scientific Co-Founder of KYAN Technologies, about one of the most promising advances in precision oncology: functional precision medicine. KYAN's technology tests multiple treatments directly against a patient's living cancer cells and uses mathematical modeling to rank which therapies are most likely to work for that individual.Together, Marybeth and Ed discuss the growing clinical evidence behind functional precision medicine, how it complements biomarker testing, its current limitations, and how patients can access the technology today. Most importantly, they explore how better data may help patients and oncologists make more informed treatment decisions—reducing unnecessary trial and error and bringing greater confidence to one of the highest-stakes decisions a cancer patient will ever face.At Outperform Cancer, we believe every important cancer decision should be as evidence-based and data-driven as possible. This conversation explores a future where choosing the next treatment relies less on educated guesswork and more on how a patient's own cancer responds in the laboratory before treatment even begins.Key Takeaways- Functional precision medicine measures how a patient's living cancer cells respond to potential treatments rather than relying solely on genomic information.- KYAN's mathematics-based platform ranks therapies that may be most effective for an individual patient's cancer.- Functional testing complements biomarker testing by providing an additional layer of information for treatment selection.- Early peer-reviewed clinical studies suggest functional precision medicine may improve treatment decision-making in several cancer types.- The technology is available to patients today but remains an emerging tool that should be used in partnership with an experienced oncology team.Episode ChaptersEdward Chow, CSO of KYAN Technologies00:00 Episode Intro04:10 Meet Edward Chow10:38 About KYAN Technologies19:05 Clinical Evidence and Real Impact33:59 From Research to Patients42:55 Insurance and Pricing56:26 Barriers and Future AdoptionResources Mentioned in This EpisodeFunctional Precision MedicineKYAN TechnologiesLearn more about KYAN's Optm.AI™ platform and patient testing services.https://kyantechnologies.com/KYAN PublicationsBrowse KYAN's peer-reviewed publications and clinical research.https://kyantechnologies.com/publications/Peer-Reviewed Research Discussed in This EpisodeFunctional Combinatorial Precision Medicine for Predicting and Optimizing Soft-Tissue Sarcoma Treatmentshttps://kyantechnologies.com/functional-combinatorial-precision-medicine-for-predicting-and-optimizing-soft-tissue-sarcoma-treatments/Rapid Therapeutic Response Prediction in Acute Myeloid Leukemiahttps://kyantechnologies.com/cancer-medicine-rapid-therapeutic-response-prediction-acute-myeloid-leukemia/Prospective Clinical Validation of a Combinatorial Functional Precision Medicine Platform in Relapsed/Refractory Non-Hodgkin Lymphomahttps://kyantechnologies.com/prospective-clinical-validation-of-a-combinatorial-functional-precision-medicine-platform-in-relapsed-refractory-non-hodgkins-lymphoma/Additional Resources Mentioned in the EpisodeFuture of Cancer Care TodayA free resource that helps patients understand emerging cancer technologies and treatment options.https://futureofcancercaretoday.org/Asthra Health (Dr. Santosh Kesari)https://asthrahealth.com/Palitra BioA precision oncology platform focused on helping patients and clinicians navigate functional precision medicine and treatment decision-making.https://palitra.bio/Kernis HealthPrecision oncology care coordination and personalized treatment navigation.https://kernis.health/Connect with Outperform Cancer🌐 Website: https://outperformcancer.com📺 YouTube: https://www.youtube.com/@OutperformCancer💼 LinkedIn: https://www.linkedin.com/company/outperform-cancer📰 Substack: https://outperformcancer.substack.com📸 Instagram: https://www.instagram.com/outperformcancer𝕏 X: https://x.com/outperformcanIf you found this episode valuable, please subscribe, share it with someone facing cancer, and visit OutperformCancer.com for more evidence-based strategies that help patients become informed partners in their care.Medical DisclaimerThe information presented in this podcast is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare team before making decisions about your medical care. Discussion of specific therapies, technologies, or research studies does not constitute an endorsement or recommendation for any individual patient. Treatment decisions should always be made in partnership with your oncology team, taking into account your unique medical history and circumstances.

When Samira Daswani was diagnosed with stage 2 triple-positive breast cancer at age 30, she quickly realized that the hardest part was not only the treatment. It was the system around the treatment — the fragmented information, the short appointments, the emotional overwhelm, and the enormous burden placed on patients and families.That experience led her to create Manta Cares, an award-winning platform built to help patients and caregivers navigate cancer with more clarity, confidence, and support.In this episode, we talk about one of the most important and underused strategies in cancer care: patient activation. Research suggests that even small acts of engagement — such as sending a message to your care team — may be associated with better outcomes. But patients cannot be activated if they do not understand their options, know what questions to ask, or feel confident enough to speak up.Samira explains how Manta Cares helps patients:- Understand diagnostic and treatment options- Prepare for oncology appointments- Track symptoms and understand severity- Know when to escalate side effects to their care team- Ask more effective questions about biomarker testing- Think about clinical trials at important treatment decision points- Access non-clinical support, including mental health, sexual health, financial toxicity, and peer supportWe also discuss Hope AI, the Manta Cares AI companion designed to help patients find relevant information, prepare better questions, and move from overwhelm toward action.For any cancer patient who has ever left an appointment thinking, “I wish I had known what to ask,” this conversation offers a practical and hopeful message: speaking up matters — and the right tools can help patients do it more effectively.Episode Chapters00:00 Episode Intro03:18 Meet Samira Daswani07:28 What Is Manta Cares?25:50 Why Patient Activation Matters33:14 Symptom Severity: When to Call Your Doctor42:27 Biomarker Testing and Asking Better Questions59:47 Clinical Trials and Treatment Decisions01:06:53 Looking Ahead: The Future of Patient ActivationVisit Manta Cares: https://mantacares.com/If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access anti-cancer strategies.YouTube: https://www.youtube.com/@OutperformCancerFacebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/

In this episode of Outperform Cancer, Marybeth Gilliam speaks with Dr. Ryan Polselli, a fellowship-trained breast imaging radiologist and founder and CEO of MammoLink, about why breast cancer screening still fails too many women — and what can be done to change that.For decades, women have been told that early detection saves lives. But too many breast cancers are still being diagnosed at later stages, when treatment is more difficult and outcomes are worse. Dr. Polselli explains that the issue is not simply whether mammograms work. The deeper problem is that the screening system is often too inconvenient, too fragmented, and not personalized enough for the women who need it.This conversation explores why annual mammograms matter, how dense breast tissue can make cancer harder to detect, why genetic risk should be identified before a cancer diagnosis whenever possible, and how mobile mammography may help close critical screening gaps. Dr. Polselli also explains how MammoLink is working to remove barriers by bringing breast imaging directly to workplaces and communities, offering a more accessible and patient-centered approach to early detection.Marybeth also shares her own experience of being diagnosed after insisting on additional testing despite a clear mammogram, reinforcing one of the most important takeaways from the episode: women should trust their bodies, understand their personal risk, and advocate for additional imaging or biopsy when something does not feel right.This episode is a call to rethink breast cancer screening as a strategy — one that combines annual screening, breast density awareness, genetic testing, risk assessment, better imaging, and easier access to help catch more cancers earlier.Episode Chapters00:00 — Episode IntroMarybeth introduces the central question of the episode: if mammograms save lives, why are women still being diagnosed with late-stage breast cancer? She explains why early detection remains one of the most powerful tools in breast cancer care, and why screening needs to become more strategic and personalized.03:50 — Meet Ryan PolselliDr. Ryan Polselli shares his background as a fellowship-trained breast imaging radiologist, former medical director of breast imaging, Navy veteran, and founder and CEO of MammoLink. He explains how his experience inside the healthcare system led him to focus on access, convenience, and better screening compliance.07:52 — About MammoLinkDr. Polselli explains the mission behind MammoLink: to remove the barriers that prevent women from getting screened. By bringing mobile mammography directly to workplaces and communities, MammoLink is designed to make breast cancer screening easier, faster, and more patient-centered.22:07 — Importance of Annual ScreeningsMarybeth and Dr. Polselli discuss why annual mammograms matter and why reported screening compliance statistics can be misleading. They explore how delayed or skipped screenings can contribute to later-stage diagnoses, and why women should not assume that a “normal” mammogram means they can ignore new symptoms.37:00 — How Patients Can Judge QualityDr. Polselli explains what patients should look for when evaluating the quality of a breast imaging center, including whether mammograms are read by breast imaging specialists, whether 3D mammography is available, how callback rates are handled, and why same-day follow-up imaging can reduce anxiety and improve the patient experience.38:39 — Mammograms and Healthcare CostsThe conversation turns to healthcare costs, reimbursement incentives, and contrast-enhanced mammography. Dr. Polselli discusses how financial structures can influence patient pathways and why some useful tools may be underused even when they could make screening easier or more effective for patients.43:22 — Breast Cancer in MenMarybeth and Dr. Polselli discuss the often-overlooked issue of breast cancer in men. While routine screening is not generally recommended for most men, Dr. Polselli emphasizes that men can develop breast cancer and should never ignore a breast lump or symptom — especially if they have a genetic risk such as a BRCA mutation.47:55 — Postpartum and Final TakeawaysMarybeth and Dr. Polselli discuss postpartum and pregnancy-associated breast cancer, including why lumps during or after pregnancy should be taken seriously. The episode closes with a clear message: know your risk, get screened, understand breast density, consider genetic testing when appropriate, and advocate for yourself if something feels wrong.Key TakeawaysAnnual mammograms matter, but the system needs to make screening easier for women to complete every year.Breast density can make cancer harder to detect on mammography, which is why some women may benefit from supplemental imaging such as ultrasound or MRI.Genetic testing is often done after a breast cancer diagnosis, but for many patients, that information could be far more powerful before cancer develops.A “normal” mammogram does not mean women should ignore a new lump, breast texture change, or symptom.Patients can ask whether their mammograms are being read by a fellowship-trained breast imaging radiologist or a breast imaging specialist.Mobile mammography may help close screening gaps by making breast imaging more accessible, convenient, and patient-centered.Men can get breast cancer too, and men with breast lumps or strong family history should take symptoms seriously.Postpartum breast cancer is an important and under-discussed risk area, and young mothers should not dismiss breast changes as “just pregnancy” or “just breastfeeding.”Connect with Dr. Ryan Polselli and MammoLinkLearn more about MammoLink and Dr. Ryan Polselli’s work to make breast cancer screening more accessible, personalized, and patient-centered:MammoLink Website: https://www.mammolink.com/Facebook: https://www.facebook.com/DrRyanPolselliLinkedIn: http://linkedin.com/in/ryanpolselliInstagram: https://www.instagram.com/ryanpolselli/If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access anti-cancer strategies.YouTube: https://www.youtube.com/@OutperformCancerFacebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/

A New Operating System for Cancer: How Sid Sijbrandij Is Outpacing an Evolving DiseaseGoing “Founder Mode” — And What Patients Can Do to Take Control of Their Own CareWhat do you do when you’re told:“There’s nothing more we can do”?That’s the moment Sid Sijbrandij faced after completing standard of care for osteosarcoma—and seeing his cancer return.In this conversation, Sid shares how that moment forced a shift in thinking: from following a treatment plan to actively building a system to stay ahead of the disease.Drawing on his experience as Co-Founder of GitLab, Sid applies principles from software development—continuous feedback, iteration, and systems thinking—to cancer care.🧠 In This EpisodeSid shares how he shifted from following a treatment plan to actively building a strategy to stay ahead of his disease.We discuss: - Why he wishes he had focused earlier on tissue preservation and deeper testing - The limitations of how tumors are typically stored (and why it matters) - How cancer can be approached as a dynamic, evolving system - The role of continuous diagnostics, including ctDNA and immune monitoring - Why most patients don’t have a clear therapeutic plan beyond the next step - The real-world challenges of accessing your own tissue and dataSid also walks through how he began exploring combination and off-label therapies, including immunotherapy approaches designed to increase immune system response.⚙️ Key InsightsMore data creates more optionsTissue quality and sequencing can shape future treatment possibilities.Cancer evolves—and treatment needs to keep up. Static, step-by-step approaches may not match the speed of the disease.The system isn’t built for this approach. Patients often face barriers around access, time, and medical liability.Risk looks different in advanced disease. For some patients, the risk of progression may outweigh treatment risks.AI is changing access to informationWhat once took months of research can now be explored in hours.🔬 Looking AheadSid also shares his experience with a personalized mRNA cancer vaccine—a promising but early technology with a favorable safety profile and growing potential as sequencing and AI improve.🚀 What Patients Can DoFor those who want to take a more active role in their care, Sid suggests: - Asking about comprehensive testing and sequencing - Preserving and accessing tumor tissue whenever possible - Using AI tools to explore treatment options and questions - Seeking second opinions and broader expertise - Considering whether additional or combination approaches may be appropriate.He also emphasizes:This approach is not for everyone.It requires time, effort, and a willingness to navigate uncertainty.🧭 Final ThoughtThis episode isn’t about rejecting standard of care. It’s about what happens when patients need—or choose—to go further. Sid’s story highlights a shift: from following a plan→ to building a system. And from treating cancer as fixed→ to engaging with it as something that evolves.Timestamps00:00 Episode Intro02:37 Meet Sid Sijbrandij09:51 What GitLab Teaches Us About Cancer Care13:54 The Tissue Hostage Problem18:39 Building a Therapeutic Ladder24:11 How AI Empowers Patients31:36 Future of Cancer Care Today37:45 Closing ThoughtsPATIENT RESOURCE: Sijbrandij Foundation, Future of Cancer Care Today.A great article about Sid’s Story: https://centuryofbio.com/p/sidSid’s personal website with links to all his healthcare information: https://sytse.com/Even One Ventures (Sid’s Venture Capital company) invests in companies overcoming the barriers of cancer care: https://www.evenone.ventures/If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access anti-cancer strategies.Facebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/

What You’ll Learn- What sulforaphane is and why it’s one of the most studied compounds in cancer research- Why broccoli sprouts contain up to 100x more sulforaphane than mature broccoli- How sulforaphane activates detoxification pathways like NRF2 and impacts inflammation- The evidence behind cancer prevention and epidemiology studies- How sulforaphane may enhance chemotherapy (chemosensitization)- Its potential role in cancer stem cells, metastasis, and recurrence- The difference between glucoraphanin vs. sulforaphane (and why it matters for absorption)- Supplements vs. whole foods: what patients need to know- Practical ways to grow, store, and use broccoli sprouts dailyKey Takeaways- Sulforaphane is a bioactive compound found in cruciferous vegetables, especially broccoli sprouts- It has been studied in hundreds of preclinical and over 100 clinical studies for its anti-cancer potential- It works across multiple cancer-related pathways including detoxification, inflammation, and cellular protection- Broccoli sprouts are one of the most effective and affordable ways to access sulforaphane- While not a cure, it may play a meaningful role in a multi-layered cancer strategy alongside standard careActionable Insights- Add broccoli sprouts to your diet regularly (one of the simplest evidence-based strategies)- If considering supplements, understand bioavailability and dosing differences- Focus on stacking strategies: nutrition, exercise, and standard treatment- Prioritize consistency over intensity (small daily actions matter)- Discuss any supplement use with your healthcare teamVisit www.outperformcancer.com for more anti-cancer strategies.Visit https://www.jedfahey.com for more information about Dr. Fahey’s research interests and a full list of his publications.Timestamps00:00 Sulforaphane & Cancer: Why It Matters02:28 Anti-Cancer Research on Sulforaphane (Studies Explained)07:15 Dr. Jed Fahey: Johns Hopkins Sulforaphane Expert08:05 What Is Sulforaphane? Broccoli & Broccoli Sprouts11:21 How Sulforaphane Works: Detox, NRF2 & Cancer Pathways15:43 Sulforaphane Dosage: Food vs Supplements21:05 Sulforaphane Supplements: Are They Effective?24:42 Best Dose of Sulforaphane (Research-Based Range)26:56 Bioavailability: Myrosinase, Gut Microbiome & Absorption29:40 Broccoli Sprouts vs Supplements: Which Is Better?33:41 Where to Buy Broccoli Sprout Seeds (High Sulforaphane)37:04 Cancer Costs & Why Prevention Matters39:36 Diet & Cancer Prevention: What Studies Show42:14 Air Pollution, Detoxification & Sulforaphane Benefits45:39 50% Cancer Risk Reduction from Cruciferous Vegetables51:48 Can Sulforaphane Prevent Metastasis?54:46 Cancer Stem Cells, Dormancy & Recurrence Risk01:03:00 NRF2 & KEAP1: Is Sulforaphane Safe in Cancer?01:09:06 Why Cancer Nutrition Science Is Confusing01:13:54 Should You Eat Broccoli Sprouts? (Expert Answer)01:15:22 Sulforaphane + Cancer Treatment (Synergy Explained)01:17:19 Food Synergy: Broccoli, Quercetin & Genistein01:19:45 Bladder Cancer & Sulforaphane Research01:22:58 Detoxing Benzene & Environmental Toxins01:25:40 GLP-1 Weight Loss & Toxin Release (Why Detox Matters)01:29:05 Diet, Doctors & Cancer Nutrition Gaps01:31:30 Broccoli Sprouts: Practical Anti-Cancer Strategy01:33:53 Medical Disclaimer

In this episode, Marybeth speaks with Dr. Nathan Fowler, Chief Medical Officer of BostonGene and former Professor of Medicine at MD Anderson Cancer Center, about why biomarker testing is helping turn personalized medicine from an idea into a reality. They discuss what biomarker testing, tumor sequencing, liquid biopsy, and ctDNA actually mean, why this information can be critical to choosing the right treatment, and why too many patients still are not being tested.Dr. Fowler explains why he believes biomarker testing should happen as early as possible, how patients can advocate for themselves, how tumor testing differs from inherited genetic testing, and when repeat testing may be needed. He also shares a remarkable story of a patient with advanced lymphoma whose biomarker matched an experimental therapy and led to a complete remission that has lasted more than a decade.Topics discussed: What biomarker-driven care actually means Why tumor sequencing can change treatment decisions The difference between tumor testing and genetic testing When liquid biopsy and ctDNA may be useful How biomarker testing can open clinical trial options Why testing should happen earlier in cancer care How BostonGene is using AI to improve precision oncologyIf you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!Facebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/Threads: https://www.threads.com/@marybethgilliam

Teri Pollastro shares how she combined standard of care treatment with bold, informed self-advocacy — and why that combination may have shaped her extraordinary 22-year survival after a stage 4 metastatic breast cancer diagnosis.Her story highlights a critical reality:Standard of care is foundational.But progress often requires patients willing to responsibly go beyond it.If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!Facebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/Threads: https://www.threads.com/@marybethgilliamBluesky: https://bsky.app/profile/outperformcancer.bsky.social

What if something as small as the sweetener in your coffee could decide whether your cancer treatment works?In this episode, Dr. Abby Overacre, a microbiome and immunology researcher at the University of Pittsburgh Medical Center, discusses her team’s new findings published in Cancer Discovery: the common artificial sweetener sucralose can undermine immunotherapy effectiveness by disrupting the gut microbiome and depleting immune-fueling amino acids like arginine.Even modest use—about three packets of Splenda per day—was associated with faster tumor growth and poorer progression-free survival in both preclinical models and cancer patients. Dr. Overacre explains how the microbiome links diet to immune response, why natural sweeteners such as stevia and monk fruit appear safer, and how fiber-rich and fermented foods can support gut and immune health during treatment.She also shares emerging research into arginine and citrulline supplementation, fecal microbiota transplants (FMT), and how restoring microbial balance could improve outcomes across cancer types, including melanoma, lung, and liver metastases.Key takeaways:—Sucralose consumption can blunt immunotherapy response.—Gut microbiome diversity plays a pivotal role in cancer outcomes.—Fiber and fermented foods strengthen immune-microbiome synergy.—Arginine and citrulline may help restore immune cell metabolism.Patients can take concrete steps to protect their microbiome during therapy.“Just three packets of sucralose a day were enough to completely blunt immunotherapy response. Patients deserve to know this.” — Dr. Abby Overacre🎧 Listen now and learn what every cancer patient on immunotherapy should know about artificial sweeteners.If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!Facebook: https://www.facebook.com/outperformcancer/LinkedIn: https://www.linkedin.com/company/outperform-cancer/Instagram: https://www.instagram.com/marybethgilliam/Threads: https://www.threads.com/@marybethgilliamBluesky: https://bsky.app/profile/outperformcancer.bsky.social

When Kristen Dahlgren was diagnosed with breast cancer, she thought she’d seen it all as an NBC correspondent. But she quickly discovered a story no one was telling: the promise of therapeutic cancer vaccines. These revolutionary treatments are showing 10+ year survival in advanced breast cancer clinical trials, and similar mind blowing results for other cancers, yet most doctors—and patients—still don’t know they exist.In this inspiring and informative episode, Kristen shares her journey from diagnosis to advocacy, the science behind cancer vaccines, and how we can all play a role in bringing them to market faster.If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!

What if your own immune system could be trained to find and destroy cancer? In this uplifting episode, Dr. Nora Disis shares the exciting breakthroughs in cancer vaccines—and why there’s real hope for patients today and in the future.If you found this valuable, LIKE, SUBSCRIBE, and SHARE to help others access life-saving information!